Active	Status	Sponsor type	Region	Phase	Filter
2 Active 0 Inactive 2 All	Not yet recruiting Recruiting Enrolling by invitation Active, not recruiting Available No longer recruiting	Industry lead sponsor Industry collaborator Coop Other	US Canada Japan Europe RoW	N/A 1 2 3 4	Highlight changes:- Show only changed items Enrollment:

Advanced Filters

2 Trials

Active Trials   

 

Export

Trial + Data / Events	Status	Ph	N	Region	Interventions	Sponsor	Conditions	Primary compl	Study compl
Morillo, Marcial Garcia
SURPASS-2, NCT04752358 / 2020-005802-24: ADP-A2M4CD8 in HLA-A2+ Subjects With MAGE-A4 Positive Esophageal or Esophagogastric Junction Cancers	Terminated	2	3	Europe, Canada, US	Autologous genetically modified ADP-A2M4CD8 cells	Adaptimmune, ICON plc	Esophageal Cancer, Esophagogastric Junction Cancer	06/23	12/23
NCT04259450 / 2019-003296-19: Study to Assess AFM24 in Advanced Solid Cancers	Completed	1/2	85	Europe, US, RoW	14 mg AFM24, 40 mg AFM24, 80 mg AFM24, 160 mg AFM24, 320 mg AFM24, 480 mg AFM24, 720 mg AFM24	Affimed GmbH	Advanced Solid Tumor	07/23	06/24